About Prospect Venture Partners

What We Do

Exceptional entrepreneurs and executives are the single most important asset in building a great business. At Prospect Venture Partners, we partner with extraordinary management teams and invest where we see a track record of innovation. Our team has more than two decades of experience and deep industry contacts to help guide outstanding executives leading early stage companies.

Since 1997, we’ve enjoyed actively participating in building and growing the companies in our portfolio. Following an initial investment, we bring significant value to our portfolio companies by sharing our knowledge, experience, and networks. We provide strategic guidance, relevant experience, deep industry contacts, and the capital necessary for success.

What We’ve Achieved

At Prospect Venture Partners, we’ve led investments in more than 50 companies that have achieved substantial clinical, commercial and regulatory achievements in their industry segments. Through our close work with their management teams, these early and growth stage companies have fueled significant returns on investment for Prospect Venture Partners funds. 

Notable investments include:

  • Amicus Therapeutics (NASDAQ: FOLD)

  • Amira Pharmaceuticals (NYSE: BMS acquired)

  • Aveo Pharmaceuticals (NASDAQ: AVEO)

  • Cabochon (Merz acquired)

  • Complete Genomics (NASDAQ: GNOM)

  • Gloucester Pharmaceuticals (NASDAQ: CELG acquired)

  • Hansen Medical (NASDAQ: HNSN)

  • Idun Pharmaceuticals (NYSE: PFE acquired)

  • Infinity Pharmaceuticals (NASDAQ: INFI)

  • Insmed (NASDAQ: INSM)

  • Jazz Pharmaceuticals (NASDAQ: JAZZ)

  • Kythera Biopharmaceuticals (NYSE: AGN acquired)

  • Millennium Pharmaceuticals (Takeda Pharmaceutical acquired)

  • Nanosys

  • NGM Biopharmaceuticals (NASDAQ: NGM)

  • Novacept (NASDAQ: HOLX acquired)

  • Opus Medical (NASDAQ: ARTC acquired)

  • Portola Pharmaceuticals (NASDAQ: PTLA)

  • Rinat Neuroscience (NYSE: PFE acquired)

  • Senomyx (NASDAQ: SNMX)

  • SentreHeart (NASDAQ: ATRC acquired)

  • SurgRx (NYSE: JNJ acquired)

  • Tercica (EURO: IPN acquired)

  • Topica Pharmaceuticals (NYSE: VRX acquired via Medicis)

  • Trubion (NYSE: EBS acquired)

Call or Visit

 

525 University Ave., Suite 1350
Palo Alto, CA 94301
(650-327-8800)

Monday – Friday: 9AM – 5PM
 

Email

Limited Partner Inquiries
TMuscarella@prospectventures.com

Learn More

Learn more about Prospect Venture Partners from:

Bloomberg
CB Insights
The Business Journals